Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161233679> ?p ?o ?g. }
- W2161233679 abstract "The chronic myeloproliferative diseases, polycythemia vera (PV), essential thrombocythemia (ET), chronic idiopathic myelofibrosis (IMF), and chronic myelogenous leukemia (CML), were grouped into a spectrum of pathogenetically related disorders of varying clinical manifestations by Dameshek in 1951.1 Recently, the World Health Organization has included the chronic eosinophilic leukemia/ hypereosinophilic syndrome, chronic neutrophilic leukemia, and systemic mast cell disease (SMCD) within this grouping. Although the origin of CML has been traced to a dysregulated protein kinase, the product of the BCR/ABL oncogene,2 and that of SMCD to 1 of 2 dysregulated receptor tyrosine kinases, c-kit, or the platelet-derived growth factor (PDGF) A receptor,3 the molecular basis of the 3 classic disorders, PV, ET, and IMF, which as a group share more similarities with each other than with CML, has been more recalcitrant to solution. However, a major insight into the molecular basis for the enhanced myeloproliferation and clonal dominance that characterizes these disorders has now been reported; the answer is another kinase, and, best of all, it all makes sense! In recent issues of the Lancet,4 Cancer Cell,5 Nature,6 and the New England Journal of Medicine,45 a single, somatic mutation in the protein tyrosine kinase Janus kinase 2 (JAK2) appears responsible for many of the features of PV, ET, and IMF, a finding that promises to impact the diagnosis and treatment of patients with these disorders and to spur additional research into the origins of dysregulated cell growth and function. The chronic myeloproliferative disorders share many features: the marrow is hypercellular and overproduces one or more of the formed elements of the blood in the absence of any apparent appropriate or pathologic stimulus; the exuberant hematopoiesis often also extends to one or more extramedullary sites. Based on studies using polymorphic genes, these disorders were shown to be clonal,7 thought to arise in a single, multipotent hematopoietic progenitor or stem cell, which comes to dominate the marrow and blood. Hematopoietic progenitor cells from the marrow or peripheral blood display altered growth properties, proliferating in serum containing cultures in the absence of exogenous hematopoietic growth factors.8 Marrow megakaryocytes are hyperplastic and variably dysplasia and are responsible for the myelofibrosis of these disorders, patients often display a tendency toward thrombotic and hemorrhagic complications in addition to their signs and symptoms related to expansion of each hematopoietic lineage. However, compared with patients with CML, transformation to acute leukemia is far less common, especially in the absence of therapy with known mutagenic agents. But despite these clinical and pathologic features, the diagnosis of an individual patient with isolated erythrocytosis or thrombocytosis is often difficult, and their treatment is usually a nonspecific suppression of hematopoiesis. Although consistent chromosomal rearrangements have been the vital roadmap pointing investigators toward the molecular pathogenesis of CML and multiple types of acute myelogenous and lymphoid leukemia, these same clues have been neither abundant nor particularly informative in the study of chronic myeloproliferative disorders; without such signs, progress in understanding PV, ET, and IMF has been slow. Nevertheless, some successes have been reported. Instances of inherited, isolated erythrocytosis and pure thrombocytosis have been solved, traced to the loss of a negative regulatory domain of the erythropoietin (EPO) receptor,9 to an abnormality in an inhibitory regulator (von Hippel Lindau protein) of the key transcription factor for EPO, hypoxia inducible factor 1 ,10 to abnormal splicing of thrombopoietin (TPO) mRNA resulting in enhanced translational efficiency and high levels of the primary humoral regulator of platelet production,11 or to 2 separate point mutations in the TPO receptor, c-Mpl.12,13 Nevertheless, none of these clinical instances are characterized by the clonal, pan-myeloid myeloproliferation that characterizes patients with chronic myeloproliferative disorders. One of the most intriguing characteristics of PV has been endogenous erythroid colony (EEC) formation, in which erythroid progenitor cells obtained from the marrow or peripheral blood proliferate in semisolid, serum-containing cultures in the absence of exogenous EPO. Although initially described for patients with PV,8 similar results can be demonstrated in a significant proportion of patients with ET and IMF, but never in healthy individuals. Thus, EEC formation has become a relatively useful, albeit cumbersome diagnostic test for myeloproliferative disorders. Unfortunately, the assay is technically demanding and is positive in only about 35% to 80% of patients with these diseases. Although initially believed to represent “EPO-independent” growth, subsequent studies revealed the phenomenon of EEC to represent hypersensitivity to the EPO present in the serum used in the cultures.14 These findings suggested that abnormalities of the EPO receptor might underlie PV. Unfortunately, except for the description of familial erythrocytosis noted earlier, the EPO receptor has been found to be completely normal in all patients with bona fide PV.15 Moreover, subsequent studies revealed that marrow and blood cells from patients with PV were hypersensitive not only to EPO but also to several other hematopoietic growth factors, including interleukin 3 (IL-3), stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GMCSF), insulin-like growth factor-1 (IGF-1), and TPO.16-19 These findings suggested that events downstream from receptor engagement might be responsible for EEC formation. Protein tyrosine phosphorylation is vital for transduction of growthpromoting signals for a wide range of cellular mitogens. However, with the cloning of the EPO receptor in 1989,20 a conundrum emerged; unlike the receptors for well-characterized mitogens such as epidermal growth" @default.
- W2161233679 created "2016-06-24" @default.
- W2161233679 creator A5008851883 @default.
- W2161233679 date "2005-01-01" @default.
- W2161233679 modified "2023-10-14" @default.
- W2161233679 title "On the Molecular Origins of the Chronic Myeloproliferative Disorders: It All Makes Sense" @default.
- W2161233679 cites W1421162947 @default.
- W2161233679 cites W1532211556 @default.
- W2161233679 cites W176998439 @default.
- W2161233679 cites W1964815717 @default.
- W2161233679 cites W1969979508 @default.
- W2161233679 cites W1980568348 @default.
- W2161233679 cites W1983337543 @default.
- W2161233679 cites W1993948601 @default.
- W2161233679 cites W2002174333 @default.
- W2161233679 cites W2005821035 @default.
- W2161233679 cites W2014420892 @default.
- W2161233679 cites W2016188929 @default.
- W2161233679 cites W2016656445 @default.
- W2161233679 cites W2028500440 @default.
- W2161233679 cites W2036180570 @default.
- W2161233679 cites W2038611905 @default.
- W2161233679 cites W2049145190 @default.
- W2161233679 cites W2053310263 @default.
- W2161233679 cites W2056867642 @default.
- W2161233679 cites W2062984099 @default.
- W2161233679 cites W2065433990 @default.
- W2161233679 cites W2065549220 @default.
- W2161233679 cites W2065810182 @default.
- W2161233679 cites W2070921472 @default.
- W2161233679 cites W2079689214 @default.
- W2161233679 cites W2096577704 @default.
- W2161233679 cites W2100869656 @default.
- W2161233679 cites W2100930825 @default.
- W2161233679 cites W2104485296 @default.
- W2161233679 cites W2108771181 @default.
- W2161233679 cites W2135034560 @default.
- W2161233679 cites W2135105253 @default.
- W2161233679 cites W2138165161 @default.
- W2161233679 cites W2144664431 @default.
- W2161233679 cites W2146228871 @default.
- W2161233679 cites W2164742594 @default.
- W2161233679 cites W2167152675 @default.
- W2161233679 cites W2218520695 @default.
- W2161233679 cites W2337577525 @default.
- W2161233679 cites W249585176 @default.
- W2161233679 cites W4231136244 @default.
- W2161233679 cites W4238316183 @default.
- W2161233679 cites W80609826 @default.
- W2161233679 doi "https://doi.org/10.1182/asheducation-2005.1.533" @default.
- W2161233679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16304432" @default.
- W2161233679 hasPublicationYear "2005" @default.
- W2161233679 type Work @default.
- W2161233679 sameAs 2161233679 @default.
- W2161233679 citedByCount "12" @default.
- W2161233679 countsByYear W21612336792013 @default.
- W2161233679 countsByYear W21612336792017 @default.
- W2161233679 countsByYear W21612336792019 @default.
- W2161233679 countsByYear W21612336792020 @default.
- W2161233679 crossrefType "journal-article" @default.
- W2161233679 hasAuthorship W2161233679A5008851883 @default.
- W2161233679 hasBestOaLocation W21612336791 @default.
- W2161233679 hasConcept C126322002 @default.
- W2161233679 hasConcept C170493617 @default.
- W2161233679 hasConcept C203014093 @default.
- W2161233679 hasConcept C2776960273 @default.
- W2161233679 hasConcept C2777129736 @default.
- W2161233679 hasConcept C2777621362 @default.
- W2161233679 hasConcept C2777938653 @default.
- W2161233679 hasConcept C2778461978 @default.
- W2161233679 hasConcept C2778837598 @default.
- W2161233679 hasConcept C2780007613 @default.
- W2161233679 hasConcept C2780076729 @default.
- W2161233679 hasConcept C2910274570 @default.
- W2161233679 hasConcept C42362537 @default.
- W2161233679 hasConcept C502942594 @default.
- W2161233679 hasConcept C71924100 @default.
- W2161233679 hasConcept C86803240 @default.
- W2161233679 hasConceptScore W2161233679C126322002 @default.
- W2161233679 hasConceptScore W2161233679C170493617 @default.
- W2161233679 hasConceptScore W2161233679C203014093 @default.
- W2161233679 hasConceptScore W2161233679C2776960273 @default.
- W2161233679 hasConceptScore W2161233679C2777129736 @default.
- W2161233679 hasConceptScore W2161233679C2777621362 @default.
- W2161233679 hasConceptScore W2161233679C2777938653 @default.
- W2161233679 hasConceptScore W2161233679C2778461978 @default.
- W2161233679 hasConceptScore W2161233679C2778837598 @default.
- W2161233679 hasConceptScore W2161233679C2780007613 @default.
- W2161233679 hasConceptScore W2161233679C2780076729 @default.
- W2161233679 hasConceptScore W2161233679C2910274570 @default.
- W2161233679 hasConceptScore W2161233679C42362537 @default.
- W2161233679 hasConceptScore W2161233679C502942594 @default.
- W2161233679 hasConceptScore W2161233679C71924100 @default.
- W2161233679 hasConceptScore W2161233679C86803240 @default.
- W2161233679 hasLocation W21612336791 @default.
- W2161233679 hasLocation W21612336792 @default.
- W2161233679 hasOpenAccess W2161233679 @default.
- W2161233679 hasPrimaryLocation W21612336791 @default.
- W2161233679 hasRelatedWork W1543124619 @default.
- W2161233679 hasRelatedWork W1546328302 @default.